Caplin Point Laboratories Share News - Latest Updates, Live News & More

Latest news about Caplin Point Laboratories

Caplin Point Laboratories Reports Strong Q2 FY26 Performance with 22.5% PAT Growth 2 days ago

Caplin Point Laboratories announced robust Q2 FY26 results with revenue from operations at ₹534.04 crores, up 10.5% YoY. Total revenue increased by 12% to ₹564.41 crores. Profit After Tax grew significantly by 22.5% to ₹160.23 crores. EBITDA rose 18.3% to ₹219.54 crores. The company's US market revenue grew by 27% to ₹221 crores in H1 FY26. Caplin Point maintains a strong financial position with ₹1,334 crores in free cash reserves. The company has expanded its presence in regulated markets with 42 ANDA approvals and is pursuing backward integration for 60% of all ANDAs. New board appointments include Mr. Ashok Partheeban and Mr. Vivek Partheeban as Additional Directors and Vice-Chairmen.

Caplin Point Laboratories Secures USFDA Approval and Expands Portfolio with $121 Million ANDA Acquisitions Oct 23, 2025

Caplin Steriles Secures USFDA Approval for Generic Milrinone Lactate Injection Sep 03, 2025

Caplin Point Laboratories Reports Robust Q1 FY26 Performance with 20.7% Growth in Net Profit Aug 07, 2025

Caplin Point Laboratories: Subsidiary to Acquire Mexican Pharma Company Triwin Pharma Jun 04, 2025

More news about Caplin Point Laboratories

15May 25

Caplin Point Laboratories: Q4 Profit Up 17%, Declares ₹3 Dividend

Caplin Point Laboratories announced strong Q4 FY2024 results with a 17.30% year-over-year increase in consolidated net profit to ₹142.60 crore. Revenue grew by 11.00% to ₹503.00 crore, while EBITDA margin expanded to 33.50%. The company declared an interim dividend of ₹3.00 per share for FY25 and projects 13-14% topline growth for FY26 with EBITDA margins expected between 32-34%.

14May 25

Caplin Point Laboratories' Subsidiary Secures FDA Approval for Haloperidol Decanoate Injection

A subsidiary of Caplin Point Laboratories has received USFDA approval for Haloperidol Decanoate Injection, an antipsychotic medication used to treat schizophrenia and other mental health disorders. This approval allows the company to market and distribute the product in the United States, potentially boosting revenue and market share. The development strengthens Caplin Point's position in the global pharmaceutical industry and provides access to the lucrative US healthcare market.

23Apr 25

Caplin Point's Subsidiary Secures USFDA Approval for Vital Injectable Drug

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has received USFDA approval for its generic Phytonadione Injectable Emulsion USP. This 10 mg/mL single-dose vial formulation treats Vitamin K deficiency. The US market for this product was valued at $18.50 million for the year ending February 2025. This approval marks Caplin Steriles' 35th USFDA approval out of 47 ANDA filings. The company plans to file over 40 more products in the next four years and is expanding globally.

03Apr 25

Caplin Point Laboratories Expands into Chilean Pharmaceutical Market through Strategic Acquisition

Caplin Point Laboratories' subsidiary, Caplin Point Far East Limited, has acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company in Chile. The acquisition, completed on April 1, 2025, involved purchasing all 3,000 shares at face value, totaling approximately USD 3,000. This move transforms Neoethicals Chile SpA into a wholly-owned subsidiary, enhancing Caplin Point's direct presence in the Chilean market for sales, marketing, and distribution of its products.

02Apr 25

Caplin Point Laboratories Expands Footprint in Chile with Strategic Acquisition

Caplin Point Laboratories' subsidiary, Caplin Point Far East Limited, has acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company in Chile. The acquisition, completed on April 1, 2025, involved purchasing 3,000 shares at 1,000 Chilean Pesos per share, totaling approximately USD 3,000. Neoethicals Chile SpA, incorporated in 2015, has shown significant growth with a turnover of 278,565,412 Chilean Pesos (USD 295,222) in 2024. This strategic move aims to establish a direct sales and distribution channel in Chile, strengthening Caplin Point's position in the South American pharmaceutical market.

27Feb 25

Caplin Steriles Secures FDA Approval for Glaucoma Treatment, Tapping into $242 Million Market

Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received USFDA approval for its ANDA for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. The approved eye drops, equivalent to COMBIGAN, are indicated for reducing elevated intraocular pressure in glaucoma or ocular hypertension patients. The product had US sales of approximately $242 million for the 12-month period ending December 2022. Caplin Steriles has developed 46 ANDAs, secured 34 approvals, and plans to expand its portfolio with over 40 products in the next four years.